Group 1 - The core focus for emerging industries in 2026 includes brain-computer interfaces, robotics, and AI applications, alongside the importance of state-owned enterprise reforms as outlined in the 14th Five-Year Plan [1] - Long-term investment themes in healthcare are centered around innovation and international expansion, with a recommendation to pay attention to high-end medical devices and innovative pharmaceuticals [1] - In the high-end medical device sector, the increasing adoption of robotics, benefits from overseas investment, recovery in hospital procurement, and growing consumer demand for medical devices are driving business growth [1] Group 2 - The AI+ healthcare direction encompasses various subfields, including medical large models, imaging, medical testing, pharmaceutical e-commerce/precision marketing, gene sequencing, and drug development [1] - Key players in the CXO and upstream life sciences value chain include globally influential leading companies, domestic clinical CRO leaders, and resource-oriented CXO enterprises [1] - The Biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in pharmaceuticals, biotechnology, and medical devices to reflect the overall performance of the biotech and healthcare-related securities [1]